Nesiritide

BNP (B-type natriuretic peptide) for acute decompensated heart failure. Vasodilatory and natriuretic peptide reducing cardiac preload and afterload in severe heart failure exacerbations.

Nesiritide is recombinant human B-type natriuretic peptide (rhBNP), a 32-amino-acid polypeptide hormone containing an intramolecular disulfide bond (Cys10-Cys26) forming a cyclic structure. BNP is an endogenous hormone secreted by ventricular myocytes in response to increased volume load or wall tension, possessing multiple physiological effects including vasodilation, natriuresis/diuresis, and suppression of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. As an intravenous agent, nesiritide is primarily used for hospitalized patients with acute decompensated heart failure (ADHF) to rapidly reduce cardiac preload and afterload and improve dyspnea.

Parameter Specification
CAS 124584-08-3
Molecular Formula C₁₄₃H₂₄₄N₅₀O₄₂S₄
Molecular Weight 3464.04 g/mol
Category Cardiovascular
Purity ≥99%
Status GMP-compliant, FDA-ready
Applications Acute decompensated heart failure, vasodilation, natriuresis

 

CAS

124584-08-3

Applications

, ,

Leave a message